These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
209 related items for PubMed ID: 23800233
1. Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging features and transcatheter arterial chemoembolization. Liu FY, Wang MQ, Duan F, Fan QS, Song P, Wang Y. BMC Gastroenterol; 2013 Jun 24; 13():105. PubMed ID: 23800233 [Abstract] [Full Text] [Related]
2. Characteristics of hepatocellular carcinoma in Egyptian patients with primary Budd-Chiari syndrome. Sakr M, Abdelhakam SM, Dabbous H, Hamed A, Hefny Z, Abdelmoaty W, Shaker M, El-Gharib M, Eldorry A. Liver Int; 2017 Mar 24; 37(3):415-422. PubMed ID: 27507647 [Abstract] [Full Text] [Related]
5. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. He M, Li Q, Shen J, Tan G, Li Q, Lai J, Wei W, Zhang Y, Zou R, Chen M, Guo R, Shi M. Cancer Med; 2019 Aug 24; 8(9):4200-4213. PubMed ID: 31207163 [Abstract] [Full Text] [Related]
7. Hepatocellular carcinoma in Budd-Chiari syndrome: enhancement patterns at dynamic gadolinium-enhanced T1-weighted MR imaging. Yang C, Xu K, Zheng J, Ma P, Hu C, Li S, Rong Y, Lu X, Zhang Q, Zu M, Hua R, Zhang L. Cell Biochem Biophys; 2014 Sep 24; 70(1):661-6. PubMed ID: 24760630 [Abstract] [Full Text] [Related]
10. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Oncology; 2011 Sep 24; 80(3-4):188-94. PubMed ID: 21709428 [Abstract] [Full Text] [Related]
11. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma. Li JJ, Zheng JS, Cui SC, Cui XW, Hu CX, Fang D, Ye LC. World J Gastroenterol; 2015 Mar 14; 21(10):3035-40. PubMed ID: 25780303 [Abstract] [Full Text] [Related]
14. Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection. Zuo CH, Xia M, Liu JS, Qiu XX, Lei X, Xu RC, Liu HC, Li JL, Li YG, Li QL, Xiao H, Hong Y, Wang XH, Zhu HZ, Wu QF, Burns M, Liu C. Asian Pac J Cancer Prev; 2015 Mar 14; 16(1):245-51. PubMed ID: 25640360 [Abstract] [Full Text] [Related]
17. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. Li JH, Xie XY, Zhang L, Le F, Ge NL, Li LX, Gan YH, Chen Y, Zhang JB, Xue TC, Chen RX, Xia JL, Zhang BH, Ye SL, Wang YH, Ren ZG. World J Gastroenterol; 2015 Apr 07; 21(13):3970-7. PubMed ID: 25852283 [Abstract] [Full Text] [Related]
18. Clinical and pathological features and surgical treatment of Budd-Chiari syndrome-associated hepatocellular carcinoma. Wang YD, Xue HZ, Zhang X, Xu ZQ, Jiang QF, Shen Q, Yu M, Li K, Jia M. Chin Med J (Engl); 2013 Apr 07; 126(19):3632-8. PubMed ID: 24112155 [Abstract] [Full Text] [Related]